RE:So much speculationStill much to be proven to the satisfaction of regulatory agencies ... one or two successes have no statistical significance when you're in a trial of 100 patients ... in this case you need sucessful results from upwards of 17-20 according to the FDA's QA sampling tables ... as the company indicated in the last NR, they're looking towards interim at the range of 20-25 results.
Since the company is not doing the trial with their own people, they've contracted it out to the sites ... in this case although the company is paying for the trial, it does not own the results until much later ... in the meantime only the principal investigator can determine what information gets released, when it gets released, and to whom it gets released ... the company might be able to release some basic intermediate information regarding numbers enrolled and treated, but release of results is, first and foremost, at the discretion of the principal investigator under the rules set up by the regulatory agency.
The principal investigator is responsible for coordinating and aggregating all the results from all the sites and presenting it to the regulators for review ... until the data and results have been reviewed and approved as successful, there's no guarantee the trial will be a success, regardless of how much one wants to believe in the science and hopes for its efficacy.
The rules in place for these trials are also meant to suppress pump and dump stock manipulation based on preliminary and minimal data releases.